Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

193 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Phase II study of neoadjuvant chemotherapy with irinotecan hydrochloride and nedaplatin followed by radical hysterectomy for bulky stage Ib2 to IIb, cervical squamous cell carcinoma: Japanese Gynecologic Oncology Group study (JGOG 1065).
Yamaguchi S, Nishimura R, Yaegashi N, Kiguchi K, Sugiyama T, Kita T, Kubushiro K, Kokawa K, Hiura M, Mizutani K, Yamamoto K, Takizawa K. Yamaguchi S, et al. Among authors: hiura m. Oncol Rep. 2012 Aug;28(2):487-93. doi: 10.3892/or.2012.1814. Epub 2012 May 14. Oncol Rep. 2012. PMID: 22614251 Clinical Trial.
Irinotecan (CPT-11) and cisplatin as first-line chemotherapy for advanced ovarian cancer.
Sugiyama T, Yakushiji M, Kamura T, Ikeda M, Umesaki N, Hasegawa K, Ishikawa M, Saji F, Hiura M, Takahashi T, Sato S, Ochiai K, Kikkawa F, Takeuchi S, Ohashi Y, Noda K; Japan CPT-11 Study Group. Sugiyama T, et al. Among authors: hiura m. Oncology. 2002;63(1):16-22. doi: 10.1159/000065715. Oncology. 2002. PMID: 12187066 Clinical Trial.
Multicenter phase II study of fertility-sparing treatment with medroxyprogesterone acetate for endometrial carcinoma and atypical hyperplasia in young women.
Ushijima K, Yahata H, Yoshikawa H, Konishi I, Yasugi T, Saito T, Nakanishi T, Sasaki H, Saji F, Iwasaka T, Hatae M, Kodama S, Saito T, Terakawa N, Yaegashi N, Hiura M, Sakamoto A, Tsuda H, Fukunaga M, Kamura T. Ushijima K, et al. Among authors: hiura m. J Clin Oncol. 2007 Jul 1;25(19):2798-803. doi: 10.1200/JCO.2006.08.8344. J Clin Oncol. 2007. PMID: 17602085 Clinical Trial.
Clinicopathological characteristics of mucinous adenocarcinoma of the ovary.
Shimada M, Kigawa J, Ohishi Y, Yasuda M, Suzuki M, Hiura M, Nishimura R, Tabata T, Sugiyama T, Kaku T. Shimada M, et al. Among authors: hiura m. Gynecol Oncol. 2009 Jun;113(3):331-4. doi: 10.1016/j.ygyno.2009.02.010. Epub 2009 Mar 10. Gynecol Oncol. 2009. PMID: 19275957
Evidence-based guidelines for treatment of uterine body neoplasm in Japan: Japan Society of Gynecologic Oncology (JSGO) 2009 edition.
Nagase S, Katabuchi H, Hiura M, Sakuragi N, Aoki Y, Kigawa J, Saito T, Hachisuga T, Ito K, Uno T, Katsumata N, Komiyama S, Susumu N, Emoto M, Kobayashi H, Metoki H, Konishi I, Ochiai K, Mikami M, Sugiyama T, Mukai M, Sagae S, Hoshiai H, Aoki D, Ohmichi M, Yoshikawa H, Iwasaka T, Udagawa Y, Yaegashi N; Japan Society of Gynecologic Oncology. Nagase S, et al. Among authors: hiura m. Int J Clin Oncol. 2010 Dec;15(6):531-42. doi: 10.1007/s10147-010-0138-6. Epub 2010 Nov 11. Int J Clin Oncol. 2010. PMID: 21069552
Clinical impact of systematic pelvic and para-aortic lymphadenectomy for pT1 and pT2 ovarian cancer: a retrospective survey by the Sankai Gynecology Study Group.
Oshita T, Itamochi H, Nishimura R, Numa F, Takehara K, Hiura M, Tanimoto H, Noma J, Hayase R, Murakami A, Fujimoto H, Kanamori Y, Kitada F, Shitsukawa K, Nagaji M, Minagawa Y, Fujiwara M, Kigawa J. Oshita T, et al. Among authors: hiura m. Int J Clin Oncol. 2013 Dec;18(6):1107-13. doi: 10.1007/s10147-012-0483-8. Epub 2012 Oct 17. Int J Clin Oncol. 2013. PMID: 23073623
193 results